|8.10||+0.1900||+2.40%||Vol 462.63K||1Y Perf 118.58%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||17.14||Analyst Rating||Strong Buy 1.25|
|Potential %||111.61||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 47.14|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||36.13||Earnings Rating||Strong Sell|
|Market Cap||442.07M||Earnings Date||4th Nov 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Nov 2021|
|Estimated EPS Next Report||-0.38|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||697.35K|
|Avg. Monthly Volume||565.67K|
|Avg. Quarterly Volume||538.42K|
Evolus Inc. (NASDAQ: EOLS) stock closed at 8.1 per share at the end of the most recent trading day (a 2.4% change compared to the prior day closing price) with a volume of 464.03K shares and market capitalization of 442.07M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 125 people. Evolus Inc. CEO is David Moatazedi.
The one-year performance of Evolus Inc. stock is 118.58%, while year-to-date (YTD) performance is 141.07%. EOLS stock has a five-year performance of %. Its 52-week range is between 2.85 and 17.38, which gives EOLS stock a 52-week price range ratio of 36.13%
Evolus Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 4.17, a price-to-sale (PS) ratio of 5.77, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -59.01%, a ROC of -92.26% and a ROE of -172.66%. The company’s profit margin is -%, its EBITDA margin is -152.70%, and its revenue ttm is $76.58 Million , which makes it $1.40 revenue per share.
Of the last four earnings reports from Evolus Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Evolus Inc.’s next earnings report date is 04th Nov 2021.
The consensus rating of Wall Street analysts for Evolus Inc. is Strong Buy (1.25), with a target price of $17.14, which is +111.61% compared to the current price. The earnings rating for Evolus Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evolus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evolus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 47.07, ATR14 : 0.63, CCI20 : -132.29, Chaikin Money Flow : -0.31, MACD : -0.78, Money Flow Index : 7.80, ROC : -24.51, RSI : 26.46, STOCH (14,3) : 11.17, STOCH RSI : 0.35, UO : 31.72, Williams %R : -88.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evolus Inc. in the last 12-months were: Crystal Muilenburg (Sold 5 362 shares of value $59 944 ), David Moatazedi (Sold 120 518 shares of value $1 312 642 ), Lauren P. Silvernail (Sold 16 992 shares of value $179 909 ), Michael M. Jafar (Sold 2 699 shares of value $20 135 ), Rui Avelar (Sold 16 992 shares of value $179 923 ), Vikram Malik (Sold 93 160 shares of value $971 283 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.